Keywords: EML4-ALK rearrangement; Non-small cell lung cancer (NSCLC); Anaplastic lymphoma kinase inhibitors (ALK inhibitors); Crizotinib; Ceritinb; Alectinib;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Alectinib; ALK inhibitor; Ceritinib; EML4-ALK; NSCLC;
Keywords: Alectinib; Crizotinib; Drug induced interstitial lung disease; Molecular target drug;
Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC
Keywords: Alectinib; Brigatinib; ALK; NSCLC; Resistance;
An UPLC-MS/MS method for the quantitation of alectinib in rat plasma
Keywords: Alectinib; UHPLC-MS/MS; Rat plasma; Pharmacokinetics;
Original ResearchEfficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria
Keywords: Alectinib; CNS metastases; NSCLC; RANO-HGG; RECIST;
ReviewDrug resistance in ALK-positiveNon-small cell lungcancer patients
Keywords: ALK; Point mutation; Crizotinib; Ceritinib; Alectinib; Lorlatinib;
Original ArticleThe second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model
Keywords: Neuroblastoma; ALK inhibitor; Alectinib; PI3K/Akt/mTOR; Apoptosis; NB; neuroblastoma; ALK; anaplastic lymphoma kinase; WT; wild type; dox; doxorubicin; DMSO; dimethyl sulfoxide; FDA; Food and Drug Administration; ALCL; anaplastic large cell lymphoma; NSCL
ReviewOptimal management of ALK-positive NSCLC progressing on crizotinib
Keywords: Alectinib; ALK-TKI; Brigatinib; Ceritinib; Crizotinib; Non-small cell lung cancer;
Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study
Keywords: Non-small cell lung cancer; Anaplastic lymphoma kinase inhibitor; Crizotinib; Alectinib; Sequential therapy; Overall survival;
Alectinib for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401)
Keywords: Alectinib; Poor performance status; ALK rearrangement; NSCLC; Pharmacokinetics;
Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer
Keywords: Alectinib; Non-small cell lung cancer; NP28673; NP28761; Pooled analysis;
Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC)
Keywords: Acalabrutinib; Alectinib; Brigatinib; Ceritinib; Crizotinib; Dabrafenib; Dasatinib; Erlotinib; Gefitinib; Ibrutinib; Imatinib; Lorlatinib; Nilotinib; Osimertinib; Rociletinib; Trametinib; Vemurafenib;
Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged Non-Small-Cell Lung Cancer: AÂ Retrospective Analysis
Keywords: Alectinib; Combined PFS; Crizotinib;
Alectinib induced CNS radiation necrosis in an ALKÂ +Â NSCLC patient with a remote (7 years) history of brain radiation
Keywords: Pseudo-progression; Radiation necrosis; Alectinib; ALK-positive non-small cell lung cancer;
Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer Relapsing on Standard Dose Alectinib
Keywords: Alectinib; ALK; Anaplastic lymphoma kinase; Leptomeningeal metastases
Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer
Keywords: Alectinib; RET; Tyrosine kinase inhibitor; Lung cancer; NSCLC;
Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review
Keywords: Acquired resistance; Alectinib; ALK inhibitor resistance; Ceritinib; Crizotinib;
I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib
Keywords: Crizotinib; Alectinib; Ceritinib; I1171 missense mutation; ALK-rearranged non-small cell lung cancer; I1171N; I1171T; I1171S;
Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance
Keywords: Tyrosine anaplastic lymphoma kinase; Alectinib; Crizotinib; Non-small cell lung cancer; Resistance; ALK mutations; EML4-ALK
Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib
Keywords: ALK; Anaplastic lymphoma kinase; Leptomeningeal metastases; Alectinib;
Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: Implications for disease assessment and management
Keywords: Radiation necrosis; Pseudoprogression; Brain metastasis; Response assessment in neuro-oncology (RANO); Anaplastic lymphoma kinase-rearranged non-small cell lung cancer; Alectinib;
Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis
Keywords: Alectinib; ALK; ALK-TKI; Ceritinib; Crizotinib; Non-small cell lung cancer;
Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer or Other Tumors
Keywords: ALK rearranged; non-small-cell lung cancer; Ceritinib; Alectinib;
Future options for ALK-positive non-small cell lung cancer
Keywords: Alectinib; ALK; ALK-TKI; CNS metastases; Ceritinib; Crizotinib; Non-small cell lung cancer; Targeted therapy
Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH5424802/RO5424802) in ALK-Rearranged NSCLC Patients Who Progressed on Crizotinib
Keywords: ALK F1174V; ALK G1202R; Crizotinib resistance; Alectinib; ALK-rearranged NSCLC; Next-generation sequencing
Overcoming the resistance to Crizotinib in patients with Non-Small Cell Lung Cancer harboring EML4/ALK translocation
Keywords: AP26113; AUY922; Alectinib; Crizotinib; EML-4/ALK translocation; LDK378; L1196 mutation
Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance
Keywords: NSCLC; ALK; ALK inhibitor; Drug resistance; Alectinib; Xenograft model